Marina Biotech elects Karis and Fletcher to board
This article was originally published in Scrip
Marina Biotech, a nucleic acid-based drug discovery and development company, has elected James Karis, who has been a board member since 2009, chairman, succeeding co-chairmen Gregory Sessler and Peter Parker, who will both continue as board members. The company has also appointed R. John Fletcher to its board, replacing Dr Chiang Li who is retiring. Mr Fletcher is the founder and CEO of Fletcher Spaght.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.